About us
Dementia is the greatest health challenge of our century.
To date there is no way to prevent it or even slow its progression, and there is an urgent need to fill the knowledge gap in our basic understanding of these diseases.
The UK Dementia Research Institute (UK DRI) is the biggest UK initiative supporting research to fill this gap.
Research in the Hall Lab, based in the UK DRI at UCL and the BHF-UK DRI Centre for Vascular Dementia Research, aims to untangle if and how the balance between the brain’s energy supply and demand shapes its activity, and especially how changes in this balance promote the emergence of vascular and Alzheimer’s dementia.
About the role
We are now recruiting a postdoctoral researcher to join the Hall Lab at UCL and work on an exciting projects defining how brain function is affected by a dysfunctional vasculature, and how blood vessels become damaged during dementia. You will interrogate the mechanisms underlying changes in neurovascular function change in the brain during dementia risk, early dementia, and during mild disruptions to the brain’s energy supply. Projects will use physiological, molecular and biochemical approaches to dissect mechanisms producing neurovascular changes observed in models of Alzheimer’s disease and vascular dementia.
The role is available from 01 February 2026 and funded by the British Heart Foundation/UK DRI for two years in the first instance.
Informal enquiries regarding the role can be addressed to Professor Catherine Hall (catherine.hall@ucl.ac.uk)
About you
You’ll have a PhD in neuroscience, life sciences, or a related field, and the ability to develop new ideas and methods, generate research hypotheses, and design experiments to test these. A strong background in statistical analysis and specialist technical expertise in one or more of the experimental methods relevant for the project is essential, as is an understanding of and interest in the research work of the UK DRI, and excellent organisational, interpersonal, and communication skills.
Key details
- Location UK DRI at UCL
- Salary: £45,103 - £48,679 per annum
- Lab: Professor Catherine Hall
About the Project
VIDA (Vascular and Immune contributors to DementiA) is a multi-institutional partnership between Alzheimer’s Society and four world-leading research sites: the University of Manchester, University of Edinburgh, Imperial, and City St George’s University of London. With projects focusing on the importance of vascular and immune mechanisms in dementia, VIDA PhD students will become the next generation of much-needed dementia researchers, contributing to breakthroughs in dementia diagnosis and treatment.
PhD studentships
VIDA students will embark upon a 4-year fully-funded PhD project at one of the four institutions above, with access to the state-of-the-art research facilities and interdisciplinary training available at all sites. Students at each site will come together as a cohort at several points during the programme, including annual conferences and residential workshop retreats which will link in with other Alzheimer’s Society Doctoral Training Centres across the UK. Students will also participate in engagement schemes with the Alzheimer’s Society and beyond, sharing the impact of their research in the community. The programme also benefits from built in opportunities for placements with leading industrial partners, and bespoke training plans including schemes to develop teaching, mentoring, and grant writing skills.
How to apply
Candidates must contact the primary supervisor before applying to discuss their interest in the project and assess their suitability.
To submit the email application, you will need:
- CV and/or cover letter
- University transcripts
- Degree certificates (any certificates/transcripts you have not yet received from your current institution can be uploaded at a later date)
- English language certificates (EU/International applicants only)
- Personal statement
- Two references
- Research proposal
Key details
- Location UK DRI at Edinburgh
- Successful applicants will receive a generous stipend of £21,800 rising by £1,000 each year, and home fees will covered.
About the Project
An opportunity has arisen for a 4-year PhD studentship within the Department of Brain Sciences at Imperial College London, funded by the VIDA DTC. VIDA (Vascular and Immune contributors to DementiA) is a multi-institutional partnership between Alzheimer’s Society and four world-leading research sites: the University of Manchester, University of Edinburgh, Imperial, and City St George’s University of London. With projects focussing on the importance of vascular and immune mechanisms in dementia, VIDA PhD students will become the next generation of much-needed dementia researchers, contributing to breakthroughs in dementia diagnosis and treatment.
VIDA students will embark upon a 4-year fully-funded PhD project at one of the four institutions above, with access to the state-of-the-art research facilities and interdisciplinary training available at all sites. Students at each site will come together as a cohort at several points during the programme, including annual conferences and residential workshop retreats, which will link in with other Alzheimer’s Society Doctoral Training Centres across the UK. Students will also participate in engagement schemes with the Alzheimer’s Society and beyond, sharing the impact of their research in the community. The programme also benefits from built-in opportunities for placements with leading industrial partners, and bespoke training plans including schemes to develop teaching, mentoring, and grant writing skills.
Project Description:
Cerebral small vessel disease (SVD) is a major cause of stroke and vascular dementia, and a key contributor to Alzheimer’s disease (AD). It affects the brain’s smallest blood vessels, arterioles, capillaries, and venules, leading to pathologies such as cerebral amyloid angiopathy (CAA) and arteriolosclerosis. Clinically, SVD is characterised by white matter hyperintensities (WMHs), lacunes, microbleeds, and enlarged perivascular spaces. Early vascular dysfunction, including impaired cerebral blood flow and increased blood–brain barrier (BBB) permeability, is strongly linked to dementia onset and progression. While circulating biomarkers (e.g. VEGF, ICAM1, PDGFB, EDN1) correlate with imaging features of SVD, no single, robust blood biomarker currently exists.
Genome-wide association studies (GWAS) show that both SVD and AD are highly heritable, sharing several genetic loci such as APOE. Most disease-associated variants are noncoding and likely influence gene regulation. Epigenomic analyses have shown that AD heritability is enriched in microglia and myeloid cells, whereas SVD heritability localises to endothelial, mural, and astrocytic cells, which are key components of the neurovascular unit. Moreover, recent multitrait analyses have revealed shared loci between AD and cardiovascular disease, including PLEC and C1Q, implicating overlapping vascular and immune pathways. However, large-scale studies defining gene regulatory mechanisms in SVD and underlying common genetic mechanisms with cardiovascular traits and other dementias remain unexplored.
We hypothesise that integrative multiomic analyses of SVD blood samples will uncover novel molecular mechanisms, biomarkers, and therapeutic targets. Objective 1 will identify gene regulatory mechanisms that are dysregulation in SVD. DNA methylation and RNA-seq will be generated from 147 longitudinally phenotyped SVD blood samples (Mild Stoke Study 2 [MSS2] cohort), with matched genotype, proteomic, and neuroimaging data. Analyses will identify DNA methylation and gene expression changes associated with SVD subtypes, dementia progression, and polygenic risk, including cross-comparison with age-, sex-, and cardiovascular risk-matched controls from the AIRWAVES cohort. Objective 2 will prioritise genetic determinants of SVD. Multitrait analysis with cardiovascular traits, together with quantitative trait locus and Mendelian randomisation analyses will link causal variants to altered gene regulation. Cross-integration with histone modification (CUT&Tag) and single-cell multiomic data alongside plasma proteomics will refine biomarker and drug target prioritisation.
This project will deliver the first integrative map of gene regulatory mechanisms in SVD, linking human genetics to molecular function. These findings will accelerate biomarker discovery and enable genetically validated therapeutic strategies for SVD and vascular dementias.
Application process:
Applicants must hold (or obtain by October 2026) a first or upper-second-class honours degree or equivalent in a neuroscience, computational neuroscience or cardiovascular science or related discipline. A Master’s degree in a related research is highly desirable but not essential.
Key details
- Location UK DRI at Imperial
- Successful applicants will receive a generous stipend of £23,800 rising by £1,000 each year, and home fees will covered*. Funding is also provided for research expenses, career development and student travel/conference attendance.
About the Project
VIDA (Vascular and Immune contributors to DementiA) is a multi-institutional partnership between Alzheimer’s Society and four world-leading research sites: the University of Manchester, University of Edinburgh, Imperial, and City St George’s University of London. With projects focusing on the importance of vascular and immune mechanisms in dementia, VIDA PhD students will become the next generation of much-needed dementia researchers, contributing to breakthroughs in dementia diagnosis and treatment.
PhD studentships
VIDA students will embark upon a 4-year fully-funded PhD project at one of the four institutions above, with access to the state-of-the-art research facilities and interdisciplinary training available at all sites. Students at each site will come together as a cohort at several points during the programme, including annual conferences and residential workshop retreats which will link in with other Alzheimer’s Society Doctoral Training Centres across the UK. Students will also participate in engagement schemes with the Alzheimer’s Society and beyond, sharing the impact of their research in the community. The programme also benefits from built in opportunities for placements with leading industrial partners, and bespoke training plans including schemes to develop teaching, mentoring, and grant writing skills.
Project Background
Cerebral small vessel disease (SVD) is the leading cause of vascular dementia, and is characterised by white matter damage which correlates closely with the degree of cognitive impairment. SVD can be sporadic or inherited, and the most common inherited form of the disease is cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is caused by a mutation in the NOTCH3 gene. While we have previously shown some of the ways in which vascular changes can affect white matter in both sporadic and inherited SVD, we still don’t fully understand how these changes occur. Additionally, much of this previous work has relied on rodent models of disease, which do not fully recapitulate changes seen in human patients.
In this project, the student will use human induced pluripotent stem cell (iPSC) derived cells to investigate interactions between vascular cells and oligodendrocytes (myelin forming cells in the brain) to better understand white matter damage in vascular dementia. We hypothesise that vascular cells derived from CADASIL patient iPSCs secrete factors which alter oligodendrocyte behaviour and function, including downstream effects of oligodendrocytes on neuronal activity and microglia. By identifying the molecules involved in these interactions, we hope to ultimately be able to disrupt these pathways to prevent disease pathology.
The aims of the project are to:
- Develop a greater understanding of vascular and endothelial dysfunction in CADASIL, including changes in secreted molecules
- Elucidate the mechanisms underlying oligodendrocyte changes in CADASIL
- Identify secreted and other factors involved in mediating vascular induced oligodendrocyte changes in CADASIL, providing possible therapeutic targets to prevent white matter damage
- Elucidate the role of oligodendrocytes in mediating neuronal and immune cell changes in CADASIL
All of these aims will have high translational relevance through use of human patient-derived cells and human post-mortem tissue
The student will be trained in iPSC cultures; differentiation of endothelial cels, mural cells, oligodendrocytes, neurons and microglia from iPSCs; functional characterisation of oligodendrocytes, neurons and microglia (including immunocytochemistry, live cell imaging and image analysis); histology, immunohistochemistry and in situ hybridisation on human post-mortem tissue; and molecular biology techniques (including ELISAs and proteomics). The student will be based primarily in Dr Rajani’s group at the University of Edinburgh, with short amounts of time spent in Prof Wang’s group at the University of Manchester to train in iPSC-mural cell differentiation.
Key details
- Location UK DRI at Edinburgh
- Successful applicants will receive a generous stipend of £21,800 rising by £1,000 each year, and home fees will covered*. Funding is also provided for research expenses, career development and student travel/conference attendance.
About us
Research from UK DRI at UCL covers the journey from the patient to the laboratory and back to the patient with improved diagnosis, biomarkers and candidate therapies put to the test.
The Busche Laboratory, based in the UK DRI at UCL, is a highly interactive environment, with strong collaborations across the UK DRI as well as with researchers at UCL and other renowned institutions.
About the role
We are seeking an exceptional individual to join on a cutting-edge research programme aimed at understanding - and ultimately reversing - neuronal and circuit dysfunction in Alzheimer’s disease.
The focus will be on linking early, cell-type-specific molecular alterations to large-scale neural circuit impairments in mouse models. The project will combine spatial omics methods with advanced techniques to record neuronal activity across large populations of cells, such as in vivo two-photon calcium imaging. A variety of experimental and analytical approaches will be applied to interrogate the mechanisms of dysfunction.
This is an outstanding opportunity to work independently on a high impact, state-of-the-art project in a stimulating, vibrant research environment.
The role is available from 01 February 2026 and funded by the UK Dementia Research Institute until 31 January 2028 in the first instance.
Informal enquiries regarding the role can be addressed to Dr Marc Aurel Busche (m.busche@ucl.ac.uk).
About you
You will hold a PhD in neuroscience, engineering, computer science, mathematics, physics, or a related field, and prior practical experience with spatial transcriptomics and related data processing/analysis. Expertise in modern molecular biology techniques such as AAV design and validation, immunostaining and confocal microscopy, single-cell RNA sequencing, quantitative in situ hybridization, and related bioinformatic skills, experience in rodent stereotactic surgery are essential for the role. Excellent interpersonal, collaboration, and communication skills are also required.
This role meets the eligibility requirements for a skilled worker certificate of sponsorship or a global talent visa under UK Visas and Immigration legislation. Therefore, UCL welcomes applications from international applicants who require a visa.
Key details
- Location UK DRI at UCL
- Salary: £43,981-£52,586
- Lab: Dr Marc Aurel Busche
About the Project
VIDA (Vascular and Immune contributors to DementiA) is a multi-institutional partnership between Alzheimer’s Society and four world-leading research sites: the University of Manchester, University of Edinburgh, Imperial, and City St George’s University of London. With projects focusing on the importance of vascular and immune mechanisms in dementia, VIDA PhD students will become the next generation of much-needed dementia researchers, contributing to breakthroughs in dementia diagnosis and treatment.
PhD studentships
VIDA students will embark upon a 4-year fully-funded PhD project at one of the four institutions above, with access to the state-of-the-art research facilities and interdisciplinary training available at all sites. Students at each site will come together as a cohort at several points during the programme, including annual conferences and residential workshop retreats which will link in with other Alzheimer’s Society Doctoral Training Centres across the UK. Students will also participate in engagement schemes with the Alzheimer’s Society and beyond, sharing the impact of their research in the community. The programme also benefits from built in opportunities for placements with leading industrial partners, and bespoke training plans including schemes to develop teaching, mentoring, and grant writing skills.
Project Background
Stroke can double the risk for a new diagnosis of dementia and can worsen cognitive trajectories in patients with existing disease (1). Stroke risk factors, the index stroke and recurrent strokes can contribute to post-stroke dementia, however it is also thought that inflammation can contribute to worsened cognitive decline (2). Systemic infections, such as pneumonia, are also a common complication of stroke recovery, and infections that occur up to 76 days after the initial stroke event have been shown to be independently associated with worsened clinical outcomes (3, 4). Infections can also cause delirium, and recurrent or severe episodes of delirium are also strongly linked to accelerated cognitive decline and the development of dementia (5). Together, this suggests that infection following stroke may contribute to increased dementia risk in survivors, however the mechanisms that drive this are poorly understood. This project will use a mouse model of ischemic stroke and induced bacterial pneumonia to investigate the relationship between systemic infection, neuroinflammation and small vessel disease in stroke recovery.
Objectives:
1. Profile the neuroinflammatory response to bacterial pneumonia and its impact on stroke injury recovery
2. Understand the impact of infection on blood brain barrier (BBB) integrity and blood vessel remodelling after stroke
3. Investigate circulating biomarkers associated with infection and worsened cognitive outcomes
Students will be comprehensively trained in all animal work and laboratory techniques and will develop experimental skills including in vivo animal models, flow cytometry, microscopy, microbiology as well as data and image analysis. This project will be carried out at the Institute for Regeneration and Repair (IRR) at the University of Edinburgh where students benefit from an excellent supportive environment with access to cutting edge facilities and both social and career development events through an active postgraduate researcher community.
Key details
- Location UK DRI at Edinburgh
- Successful applicants will receive a generous stipend of £21,800 rising by £1,000 each year, and home fees will covered*. Funding is also provided for research expenses, career development and student travel/conference attendance.
About the Project
VIDA (Vascular and Immune contributors to DementiA) is a multi-institutional partnership between Alzheimer’s Society and four world-leading research sites: the University of Manchester, University of Edinburgh, Imperial, and City St George’s University of London. With projects focusing on the importance of vascular and immune mechanisms in dementia, VIDA PhD students will become the next generation of much-needed dementia researchers, contributing to breakthroughs in dementia diagnosis and treatment.
PhD studentships
VIDA students will embark upon a 4-year fully-funded PhD project at one of the four institutions above, with access to the state-of-the-art research facilities and interdisciplinary training available at all sites. Students at each site will come together as a cohort at several points during the programme, including annual conferences and residential workshop retreats which will link in with other Alzheimer’s Society Doctoral Training Centres across the UK. Students will also participate in engagement schemes with the Alzheimer’s Society and beyond, sharing the impact of their research in the community. The programme also benefits from built in opportunities for placements with leading industrial partners, and bespoke training plans including schemes to develop teaching, mentoring, and grant writing skills.
Project Background
Neurovascular dysfunction is increasingly recognised as a key contributor to Alzheimer’s Disease (AD)1, yet the sequence of vascular events and underlying molecular mechanisms remain unclear. Core abnormalities, such as cerebral hypoperfusion2, blood-brain barrier (BBB) disruption, and impaired cerebrovascular reactivity3, exacerbate amyloid- and tau-associated neurotoxicity. Pericytes, contractile mural cells that support BBB integrity and neurovascular coupling, are particularly vulnerable to amyloid-beta (Aβ) toxicity. Soluble Aβ oligomers induce pericyte contraction and death, leading to BBB leakage and vascular dysfunction4. Plasma and microvascular proteomic studies have identified early endothelial and pericyte stress signatures, including inflammation and oxidative stress, offering mechanistic insight into vascular failure in AD5.
We hypothesise that combining in vivo imaging of pericyte dynamics with plasma and microvascular proteomic profiling in a mouse model of amyloidosis will reveal the chronology and interplay of vascular dysfunction triggered by Aβ toxicity.
The project has two objectives:
(1) to functionally and mechanistically characterise microvascular impairment using two-photon and laser-speckle imaging complemented by ex vivo confocal and light-sheet microscopy; and
(2) to develop MRI-based biomarkers of amyloid-driven vascular dysfunction. Longitudinal MRI will quantify cerebrovascular reactivity, perfusion, and BBB permeability, and these imaging readouts will be correlated with vascular and plasma proteomic molecular signatures to identify robust functional biomarkers.
By establishing the temporal sequence of pericyte degeneration, BBB breakdown, and perfusion deficits over timescales of days to weeks (up to approximately 8 weeks) and linking these to molecular changes, this multidisciplinary project will elucidate the mechanistic drivers of neurovascular dysfunction in AD. The results will provide clinically relevant imaging and molecular biomarkers for early-stage detection and guide translational strategies for diagnosis and therapeutic intervention.
Key details
- Location UK DRI at Edinburgh
- Salary: The studentship is funded through the Alzheimer’s Research UK (ARUK) for 4 years and will cover UK university tuition fees (home fees only). The studentship will also pay an annual stipend based on the standard ARUK set stipend rate.
About us
The UK Dementia Research Institute (UK DRI) is a globally leading multidisciplinary research institute of over 900 staff investigating the spectrum of neurodegenerative disorders causing dementia, driving a step change in our understanding of neurodegeneration, and accelerating the discovery, development and delivery of interventions that will help diagnose, treat, and ultimately prevent dementia.
The Bourdenx Lab at the UK DRI, led by Dr Mathieu Bourdenx, focuses on how age-related loss of cellular fitness in the brain drives neurodegeneration. Using cutting-edge spatial biology and single-cell approaches, the lab maps vulnerability and resilience in ageing brains. By combining molecular cell biology with computational tools - including AI-driven hypothesis generation - we aim to uncover novel mechanisms and therapeutic targets for Alzheimer’s disease and related dementias.
About the role
We are seeking a Research Technician to provide technical support by assisting lab members with a range of experimental procedures, data analysis, and general laboratory organisation. The role involves not only applying existing laboratory methods but also contributing to their optimisation and expansion. You will work under the direct supervision of the Group Leader, but you will also be expected to work independently and contribute to the design and execution of experiments on a day-to-day basis.
There may also be opportunities to support other members of the group in administering and monitoring anaesthesia in mice and in performing surgical procedures.
The post is available immediately and is funded by the Medical Research Council until 31 December 2026 in the first instance.
About you
You will hold a BSc (or equivalent) in a relevant discipline such as Neuroscience, Physiology, Biology, Medicine, or a related field. You will have hands-on experience with histological techniques, including perfusions, cryosectioning, and tissue staining (immunohistochemistry and immunofluorescence), as well as experience with in situ hybridisation and RNA biology. Experience with scientific programming (e.g., Python or R) and with imaging and image analysis using tools such as confocal microscopy, ImageJ, or Imaris is essential as is knowledge of neuroscience-related themes.
Key details
- Location UK DRI at UCL
- Salary: £36,433-£41,833 per annum
- Lab: Dr Mathieu Bourdenx